Short answer

Nuvation Bio Inc. (NUVB) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $32M (up 555.6% year over year) with net income of −$63M.

Q2 2026 key financials · XBRL

Revenue: $32M; +555.6% YoY · −61.9% QoQ
Net income: −$63M; −6.5% YoY · −1264.4% QoQ
Operating margin: -161.1%
EPS (diluted): −$0.18; −5.9% YoY · −1900.0% QoQ

Source: XBRL data from the Nuvation Bio Inc. (NUVB) Q2 2026 10-Q on SEC EDGAR. USD.

Nuvation Bio Inc. Q2 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

Revenue $31.7M, up $26.9M YoY from $4.8M, driven by IBTROZI product revenue of $23.2M
Collaboration revenue $8.5M, up $4.9M YoY, led by product supply and royalty revenue increases
Total costs $82.7M, up $14.3M YoY, with R&D $30.7M and SG&A $42.6M
Cash, equivalents and marketable securities $661.0M; $279.1M notes proceeds and $58.7M debt repayment
FDA supplemental IBTROZI application target action date January 4, 2027; expenses expected to increase substantially

Risk Factors

Newly added commercialization risk triggered by June 2025 FDA approval and U.S. launch of IBTROZI, the company’s only FDA-marketed product
Most material update: limited commercial experience now threatens launch execution, sales-force sizing, distribution, and near-term profitability
Regulatory risk: U.S. and China approvals carry post-marketing requirements and commitments, with potential penalties or withdrawal for noncompliance
Competitive risk: safer, cheaper, or more convenient ROS1+ NSCLC therapies could reduce IBTROZI adoption and commercial viability
Financial risk: profitability depends primarily on IBTROZI sales, while indebtedness and debt-service obligations may constrain operating funding

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Nuvation Bio Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.

Start free